Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
2 Adipocytokine signaling pathway 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
4 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
5 Alcoholic liver disease 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
6 Alcoholic liver disease 💬
1件: C5AR1 💬 Avacopan 💬 Avacopan 4件: 43, 44, 66, 222 💬
7 Allograft rejection 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
8 Allograft rejection 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
9 Allograft rejection 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
10 Allograft rejection 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
11 Asthma 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
12 Asthma 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
13 Asthma 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
14 Autoimmune thyroid disease 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
15 Autoimmune thyroid disease 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
16 Autoimmune thyroid disease 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
17 Autoimmune thyroid disease 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
18 Cell adhesion molecules 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
19 cGMP-PKG signaling pathway 💬
1件: OPRD1 💬 Naltrexone hydrochloride 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
20 cGMP-PKG signaling pathway 💬
1件: OPRD1 💬 Naltrexone 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
21 Chemical carcinogenesis - receptor activation 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
22 Chemical carcinogenesis - receptor activation 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
23 Chemokine signaling pathway 💬
2件: JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
24 Chemokine signaling pathway 💬
2件: JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
25 Cholinergic synapse 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
26 Cholinergic synapse 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
27 Complement and coagulation cascades 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
28 Complement and coagulation cascades 💬
1件: C5AR1 💬 Avacopan 💬 Avacopan 4件: 43, 44, 66, 222 💬
29 Coronavirus disease - COVID-19 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
30 Coronavirus disease - COVID-19 💬
1件: C5AR1 💬 Avacopan 💬 Avacopan 4件: 43, 44, 66, 222 💬
31 Coronavirus disease - COVID-19 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
32 Coronavirus disease - COVID-19 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
33 Coronavirus disease - COVID-19 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
34 Cytokine-cytokine receptor interaction 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
35 Cytokine-cytokine receptor interaction 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
36 Cytokine-cytokine receptor interaction 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
37 Cytokine-cytokine receptor interaction 💬
1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
38 Cytokine-cytokine receptor interaction 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
39 Cytokine-cytokine receptor interaction 💬
1件: TNFSF13B 💬 Belimumab 💬 Belimumab 14件: 11, 13, 43, 44, 46, 48, 49, 51, 53, 63, 66, 95, 222, 296 💬
40 Cytokine-cytokine receptor interaction 💬
1件: TSLP 💬 Tezepelumab 💬 Tezepelumab 3件: 44, 45, 98 💬
41 Drug metabolism - other enzymes 💬
2件: IMPDH, IMPDH 💬 Mycophenolate mofetil hydrochloride 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 93, 95, 96, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
42 Drug metabolism - other enzymes 💬
2件: IMPDH, IMPDH 💬 Mycophenolate mofetil 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 93, 95, 96, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
43 Drug metabolism - other enzymes 💬
2件: IMPDH, IMPDH 💬 Mycophenolate sodium 💬 Mycophenolic acid 37件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 84, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
44 Drug metabolism - other enzymes 💬
2件: IMPDH, IMPDH 💬 Mycophenolic acid 💬 Mycophenolic acid 37件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 84, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
45 Drug metabolism - other enzymes 💬
1件: RRM1 💬 Fludarabine phosphate 💬 Fludarabine 25件: 11, 13, 19, 28, 34, 35, 36, 44, 46, 49, 51, 60, 61, 62, 65, 85, 96, 107, 164, 222, 283, 284, 285, 286, 326 💬
46 Drug metabolism - other enzymes 💬
1件: RRM1 💬 Fludarabine 💬 Fludarabine 25件: 11, 13, 19, 28, 34, 35, 36, 44, 46, 49, 51, 60, 61, 62, 65, 85, 96, 107, 164, 222, 283, 284, 285, 286, 326 💬
47 Efferocytosis 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
48 Efferocytosis 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
49 Epstein-Barr virus infection 💬
3件: JAK1, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
50 Epstein-Barr virus infection 💬
3件: JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
51 Estrogen signaling pathway 💬
1件: OPRM1 💬 Naltrexone hydrochloride 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
52 Estrogen signaling pathway 💬
1件: OPRM1 💬 Naltrexone 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
53 Fc epsilon RI signaling pathway 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
54 Fc epsilon RI signaling pathway 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
55 Fc epsilon RI signaling pathway 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
56 Folate biosynthesis 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
57 Folate biosynthesis 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
58 Folate transport and metabolism 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
59 Folate transport and metabolism 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
60 Glutathione metabolism 💬
1件: RRM1 💬 Fludarabine phosphate 💬 Fludarabine 25件: 11, 13, 19, 28, 34, 35, 36, 44, 46, 49, 51, 60, 61, 62, 65, 85, 96, 107, 164, 222, 283, 284, 285, 286, 326 💬
61 Glutathione metabolism 💬
1件: RRM1 💬 Fludarabine 💬 Fludarabine 25件: 11, 13, 19, 28, 34, 35, 36, 44, 46, 49, 51, 60, 61, 62, 65, 85, 96, 107, 164, 222, 283, 284, 285, 286, 326 💬
62 Graft-versus-host disease 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
63 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
64 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
65 Hematopoietic cell lineage 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
66 Hematopoietic cell lineage 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
67 Hematopoietic cell lineage 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
68 Hematopoietic cell lineage 💬
1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
69 Hematopoietic cell lineage 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
70 Hematopoietic cell lineage 💬
1件: MS4A1 💬 Obinutuzumab 💬 Obinutuzumab 5件: 43, 44, 49, 63, 222 💬
71 Hematopoietic cell lineage 💬
1件: MS4A1 💬 Rituximab 💬 Rituximab 52件: 11, 13, 14, 19, 26, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 172, 220, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
72 Hepatitis B 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
73 Hepatitis B 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
74 Hepatitis C 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
75 Hepatitis C 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
76 Herpes simplex virus 1 infection 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
77 Herpes simplex virus 1 infection 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
78 Herpes simplex virus 1 infection 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
79 HIF-1 signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
80 Hormone signaling 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
81 Hormone signaling 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
82 Hormone signaling 💬
3件: OPRD1, OPRK1, OPRM1 💬 Naltrexone hydrochloride 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
83 Hormone signaling 💬
3件: OPRD1, OPRK1, OPRM1 💬 Naltrexone 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
84 Human cytomegalovirus infection 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
85 Human cytomegalovirus infection 💬
1件: JAK1 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
86 Human cytomegalovirus infection 💬
1件: JAK1 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
87 Human papillomavirus infection 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
88 Human papillomavirus infection 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
89 Human T-cell leukemia virus 1 infection 💬
2件: JAK1, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
90 Human T-cell leukemia virus 1 infection 💬
2件: JAK1, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
91 IL-17 signaling pathway 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
92 IL-17 signaling pathway 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
93 IL-17 signaling pathway 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
94 Inflammatory bowel disease 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
95 Inflammatory bowel disease 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
96 Inflammatory bowel disease 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
97 Influenza A 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
98 Influenza A 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
99 Intestinal immune network for IgA production 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
100 Intestinal immune network for IgA production 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
101 Intestinal immune network for IgA production 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
102 Intestinal immune network for IgA production 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
103 Intestinal immune network for IgA production 💬
1件: TNFSF13B 💬 Belimumab 💬 Belimumab 14件: 11, 13, 43, 44, 46, 48, 49, 51, 53, 63, 66, 95, 222, 296 💬
104 JAK-STAT signaling pathway 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
105 JAK-STAT signaling pathway 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
106 JAK-STAT signaling pathway 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
107 JAK-STAT signaling pathway 💬
1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
108 JAK-STAT signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
109 JAK-STAT signaling pathway 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
110 JAK-STAT signaling pathway 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
111 JAK-STAT signaling pathway 💬
1件: TSLP 💬 Tezepelumab 💬 Tezepelumab 3件: 44, 45, 98 💬
112 Kaposi sarcoma-associated herpesvirus infection 💬
1件: CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
113 Kaposi sarcoma-associated herpesvirus infection 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
114 Kaposi sarcoma-associated herpesvirus infection 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
115 Leishmaniasis 💬
2件: JAK1, JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
116 Leishmaniasis 💬
2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
117 Lipid and atherosclerosis 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
118 Lipid and atherosclerosis 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
119 Measles 💬
3件: JAK1, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
120 Measles 💬
3件: JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
121 Morphine addiction 💬
1件: OPRM1 💬 Naltrexone hydrochloride 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
122 Morphine addiction 💬
1件: OPRM1 💬 Naltrexone 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
123 Necroptosis 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
124 Necroptosis 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
125 Neuroactive ligand signaling 💬
3件: OPRD1, OPRK1, OPRM1 💬 Naltrexone hydrochloride 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
126 Neuroactive ligand signaling 💬
3件: OPRD1, OPRK1, OPRM1 💬 Naltrexone 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
127 Neuroactive ligand-receptor interaction 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
128 Neuroactive ligand-receptor interaction 💬
1件: C5AR1 💬 Avacopan 💬 Avacopan 4件: 43, 44, 66, 222 💬
129 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Prednisolone 💬 Prednisolone 41件:  3 , 11, 13, 14, 18, 25, 26, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 60, 61, 63, 64, 66, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 251, 269, 271, 296, 299, 300 💬
130 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Prednisone 💬 Prednisone 54件:  2 , 11, 13, 14, 18, 19, 26, 28, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 60, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 90, 93, 95, 96, 97, 113, 145, 162, 164, 205, 222, 224, 228, 251, 269, 283, 285, 288, 299, 300, 303, 307, 331 💬
131 Neuroactive ligand-receptor interaction 💬
3件: OPRD1, OPRK1, OPRM1 💬 Naltrexone hydrochloride 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
132 Neuroactive ligand-receptor interaction 💬
3件: OPRD1, OPRK1, OPRM1 💬 Naltrexone 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
133 Neutrophil extracellular trap formation 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
134 Neutrophil extracellular trap formation 💬
1件: C5AR1 💬 Avacopan 💬 Avacopan 4件: 43, 44, 66, 222 💬
135 NF-kappa B signaling pathway 💬
1件: TNFSF13B 💬 Belimumab 💬 Belimumab 14件: 11, 13, 43, 44, 46, 48, 49, 51, 53, 63, 66, 95, 222, 296 💬
136 NOD-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
137 NOD-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
138 Non-alcoholic fatty liver disease 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
139 Non-small cell lung cancer 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
140 Non-small cell lung cancer 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
141 One carbon pool by folate 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
142 One carbon pool by folate 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
143 Osteoclast differentiation 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
144 Osteoclast differentiation 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
145 Pancreatic cancer 💬
1件: JAK1 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
146 Pancreatic cancer 💬
1件: JAK1 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
147 Pathways in cancer 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
148 Pathways in cancer 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
149 Pathways in cancer 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
150 Pathways in cancer 💬
1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
151 Pathways in cancer 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
152 Pathways in cancer 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
153 Pathways in cancer 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
154 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: JAK1, JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
155 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
156 Pertussis 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
157 PI3K-Akt signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
158 PI3K-Akt signaling pathway 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
159 PI3K-Akt signaling pathway 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
160 Primary immunodeficiency 💬
1件: JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
161 Primary immunodeficiency 💬
1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
162 Prion disease 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
163 Prolactin signaling pathway 💬
1件: JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
164 Prolactin signaling pathway 💬
1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
165 Purine metabolism 💬
2件: IMPDH, IMPDH 💬 Mycophenolate mofetil 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 93, 95, 96, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
166 Purine metabolism 💬
2件: IMPDH, IMPDH 💬 Mycophenolate mofetil hydrochloride 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 93, 95, 96, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
167 Purine metabolism 💬
2件: IMPDH, IMPDH 💬 Mycophenolate sodium 💬 Mycophenolic acid 37件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 84, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
168 Purine metabolism 💬
2件: IMPDH, IMPDH 💬 Mycophenolic acid 💬 Mycophenolic acid 37件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 84, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
169 Purine metabolism 💬
1件: RRM1 💬 Fludarabine phosphate 💬 Fludarabine 25件: 11, 13, 19, 28, 34, 35, 36, 44, 46, 49, 51, 60, 61, 62, 65, 85, 96, 107, 164, 222, 283, 284, 285, 286, 326 💬
170 Purine metabolism 💬
1件: RRM1 💬 Fludarabine 💬 Fludarabine 25件: 11, 13, 19, 28, 34, 35, 36, 44, 46, 49, 51, 60, 61, 62, 65, 85, 96, 107, 164, 222, 283, 284, 285, 286, 326 💬
171 Pyrimidine metabolism 💬
1件: RRM1 💬 Fludarabine phosphate 💬 Fludarabine 25件: 11, 13, 19, 28, 34, 35, 36, 44, 46, 49, 51, 60, 61, 62, 65, 85, 96, 107, 164, 222, 283, 284, 285, 286, 326 💬
172 Pyrimidine metabolism 💬
1件: RRM1 💬 Fludarabine 💬 Fludarabine 25件: 11, 13, 19, 28, 34, 35, 36, 44, 46, 49, 51, 60, 61, 62, 65, 85, 96, 107, 164, 222, 283, 284, 285, 286, 326 💬
173 Regulation of actin cytoskeleton 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
174 Rheumatoid arthritis 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
175 Rheumatoid arthritis 💬
1件: TNFSF13B 💬 Belimumab 💬 Belimumab 14件: 11, 13, 43, 44, 46, 48, 49, 51, 53, 63, 66, 95, 222, 296 💬
176 Signaling pathways regulating pluripotency of stem cells 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
177 Signaling pathways regulating pluripotency of stem cells 💬
3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
178 Sphingolipid signaling pathway 💬
1件: OPRD1 💬 Naltrexone hydrochloride 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
179 Sphingolipid signaling pathway 💬
1件: OPRD1 💬 Naltrexone 💬 Naltrexone 12件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
180 Staphylococcus aureus infection 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
181 Staphylococcus aureus infection 💬
1件: C5AR1 💬 Avacopan 💬 Avacopan 4件: 43, 44, 66, 222 💬
182 Systemic lupus erythematosus 💬
1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
183 Systemic lupus erythematosus 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
184 T cell receptor signaling pathway 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
185 T cell receptor signaling pathway 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
186 T cell receptor signaling pathway 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
187 Th1 and Th2 cell differentiation 💬
1件: IL5 💬 Depemokimab 💬 Depemokimab 2件: 44, 45 💬
188 Th1 and Th2 cell differentiation 💬
1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
189 Th1 and Th2 cell differentiation 💬
1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
190 Th1 and Th2 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
191 Th1 and Th2 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
192 Th17 cell differentiation 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
193 Th17 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
194 Th17 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
195 Toll-like receptor signaling pathway 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
196 Toll-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
197 Toll-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
198 Toxoplasmosis 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
199 Toxoplasmosis 💬
3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
200 Transcriptional misregulation in cancer 💬
1件: CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
201 Tuberculosis 💬
2件: JAK1, JAK2 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
202 Tuberculosis 💬
2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
203 Type I diabetes mellitus 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
204 Viral carcinogenesis 💬
2件: JAK1, JAK3 💬 Tofacitinib citrate 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
205 Viral carcinogenesis 💬
2件: JAK1, JAK3 💬 Tofacitinib 💬 Tofacitinib 22件:  2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬
206 Viral myocarditis 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
207 Viral protein interaction with cytokine and cytokine receptor 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
208 Virion - Adenovirus 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬